INM Earnings InMed Pharmaceuticals Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–27 of 27
| Q1 2027 | 2026-09-30 | -0.42 | 2026-11-03 | 10-Q |
| Q4 2026 (derived) | 2026-06-30 | -1.44 | 2026-09-09 | 10-K |
| FY 2026 | 2026-06-30 | -3.12 | 2026-09-09 | 10-K |
| Q3 2026 | 2026-03-31 | -0.73 | 2026-05-06 | 10-Q |
| Q2 2026 | 2025-12-31 | -0.51 | 2026-02-11 | 10-Q |
| Q1 2026 | 2025-09-30 | -0.44 | 2025-11-06 | 10-Q |
| Q4 2025 (derived) | 2025-06-30 | -0.07 | 2025-09-23 | 10-K |
| FY 2025 | 2025-06-30 | -8.36 | 2025-09-23 | 10-K |
| Q3 2025 | 2025-03-31 | -1.94 | 2025-05-12 | 10-Q |
| Q2 2025 | 2024-12-31 | -3.64 | 2025-02-12 | 10-Q |
| Q1 2025 | 2024-09-30 | -2.71 | 2024-11-14 | 10-Q |
| Q4 2024 (derived) | 2024-06-30 | 2.39 | 2024-09-30 | 10-K |
| FY 2024 | 2024-06-30 | -20.14 | 2024-09-30 | 10-K |
| Q3 2024 | 2024-03-31 | -3.58 | — | — |
| Q2 2024 | 2023-12-31 | -3.71 | 2024-02-13 | 10-Q |
| Q1 2024 | 2023-09-30 | -15.24 | 2023-11-14 | 10-Q |
| Q4 2023 (derived) | 2023-06-30 | 46.40 | 2023-09-29 | 10-K |
| FY 2023 | 2023-06-30 | -65.00 | 2023-09-29 | 10-K |
| Q3 2023 | 2023-03-31 | -12.00 | 2023-05-15 | 10-Q |
| Q2 2023 | 2022-12-31 | -18.20 | 2023-02-17 | 10-Q |
| Q1 2023 | 2022-09-30 | -81.20 | 2022-11-14 | 10-Q |
| Q4 2022 (derived) | 2022-06-30 | -262.60 | 2022-09-23 | 10-K |
| FY 2022 | 2022-06-30 | -663.40 | 2022-09-23 | 10-K |
| Q3 2022 | 2022-03-31 | -122.80 | — | — |
| Q2 2022 | 2021-12-31 | -154.60 | — | — |
| Q1 2022 | 2021-09-30 | -123.40 | — | — |
| FY 2021 | 2021-06-30 | -759.20 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.